- ChemTrak Inc.
- Takeda Oncology
- Eli Lilly & Co.
- CuraGen Corp.
- Genaissance Pharmaceuticals Inc.
- Nuvelo Inc.
- Oxagen Ltd.
- Gemini Genomics AB
- Millennium Predictive Medicine Inc.
- SmithKline Beecham
- Incyte Corp.
- Johnson & Johnson
- Myriad Genetics Inc.
- Pharmacia & Upjohn Inc.
- Genset SA
- Roche Diagnostic Systems Inc.
- Igen International Inc.
- Millennium BioTherapeutics Inc.
- MD Anderson Cancer Center
- University of Pittsburgh
- Harvard Medical School
- Ore Pharmaceuticals Inc.
- Applied Biosystems Inc.
- Oxford Molecular Group PLC
- Synteni Inc.
- Oxford GlycoSciences PLC
- PCS Health Systems Inc.
- Rite Aid Corp.
- Fujirebio buys Centocor's oncology Dx business for $37.5mm
- Monsanto pays $218mm in genomics pact with Millennium
- SmithKline, Incyte form 50/50 diagnostics JV, diaDeXus LLC
- Ciba-Geigy AG to hold 49.9% of Chiron
- P&U signs pharmacogenomics alliance with Genset
- Nanogen, Becton create joint venture to develop diagnostics
- Lilly & Millennium in atherosclerosis genomic deal
- Millennium and Mayo work together in gene characterization
- Incyte and Oxford GlycoSciences create proteomic databases
- SmithKline in $125 million deal with Human Genome Sciences
- Lilly to acquire PCS, largest US PBM, for $4 billion
- Lilly finally exits its losing PBM deal
Ask The Analyst
Please Note: Click here for more information on the Ask the Analyst service.
Your question has been successfully sent to the email address below and we will get back as soon as possible. email@example.com.
All fields are required.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.